(Glioma) Oncolytic Virus Therapy for Cancer Treatment Now Available in Japan

• November 8, 2021
• Reading time: 1 minute

On November 1, 2021, Daiichi Sankyo announced the commercial launch in Japan of teserpaturev, an oncolytic virus drug for treating malignant glioma.

Teserpaturev is a cancer treatment virus drug co-developed with Professor Tomoki Todo of the Institute of Medical Science at the University of Tokyo. Its manufacturing and marketing approval was granted based on a Phase 2 clinical trial led by Professor Todo in patients with malignant glioma.

Dosing Schedule for Adult Malignant Glioma Patients

• 1st and 2nd administrations: Treatment cycle of 5–14 days
• 3rd through 6th administrations: Treatment cycle of every 4 weeks

Daiichi Sankyo stated: "We hope this product will provide a new treatment option for malignant glioma patients with unmet medical needs, thereby contributing to patients' well-being."

In June 2021, teserpaturev received conditional and time-limited manufacturing and marketing authorization as a regenerative medicine product for treating malignant glioma. It is currently only available at clinical trial institutions.

Source: https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202111/20211101_J.pdf

• Clinical trial drug

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4